[Therapeutic effects of a combination treatment with flomoxef and tobramycin against infections complicated with hematological disorders].

Publisher: Japan Antibiotics Research Assn Country of Publication: Japan NLM ID: 0154402 Publication Model: Print Cited Medium: Print ISSN: 0368-2781 (Print) Linking ISSN: 03682781 NLM ISO Abbreviation: Jpn J Antibiot Subsets: MEDLINE

Original Publication: Tokyo, Japan Antibiotics Research Assn.

Immunocompromised Host*; Cephalosporins/*therapeutic use ; Drug Therapy, Combination/*therapeutic use ; Hematologic Diseases/*complications ; Opportunistic Infections/*drug therapy ; Sepsis/*drug therapy ; Tobramycin/*therapeutic use; Adult ; Aged ; Cephalosporins/administration & dosage ; Drug Therapy, Combination/administration & dosage ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neutropenia/complications ; Opportunistic Infections/complications ; Sepsis/complications ; Tobramycin/administration & dosage

The efficacy and safety of a combination regimen using flomoxef (FMOX) and tobramycin (TOB) were evaluated in the treatment of infections complicated with hematological disorders. The primary diseases in 40 patients included acute leukemia, malignant lymphoma and others. Complicated infections included 35 cases with suspected septicemia, 4 cases with septicemia and 1 case with pleuritis. Clinical responses were excellent in 10 (25.0%), good in 14 (35.0%), fair in 2 (5.0%) and poor in 14 (35.0%). The efficacy rate was 73.1% in patients with neutrophil counts higher than 501/microliters after administration, but it was 35.7% in patients with counts less than 501/microliters; the difference was statistically significant. No side effects were observed in any of the 40 patients. Abnormal laboratory data in liver functions were identified in 1 patient (2.5%). Degree of this abnormality was very slight, and the continuation of treatment was not disturbed. In conclusion, this combination therapy of FMOX and TOB thus appears to be useful and safe in therapies for infections complicated with hematological disorders.

0 (Cephalosporins)
V9E5U5XF42 (flomoxef)
VZ8RRZ51VK (Tobramycin)

Date Created: 19920801 Date Completed: 19921211 Latest Revision: 20161116

20221208

1433894